AC Immune (ACIU) Non-Current Deffered Revenue (2019 - 2025)
AC Immune (ACIU) reported Non-Current Deffered Revenue of $2.9 million for Q4 2025, down 43.78% year-over-year from $5.2 million in Q4 2024, and down 13.3% on a QoQ basis from $3.4 million in Q3 2025.
AC Immune (ACIU) has 4 years of Non-Current Deffered Revenue data on file, last reported at $2.9 million in Q4 2025.
- Quarterly Non-Current Deffered Revenue fell 43.78% year-over-year to $2.9 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $2.9 million (down 43.78% YoY) and the FY2025 annual result came in at $2.8 million, down 45.8% from the prior year.
- Non-Current Deffered Revenue retreated to $2.9 million in Q4 2025 per ACIU's latest filing, from $3.4 million in the prior quarter.
- Across five years, Non-Current Deffered Revenue topped out at $102.9 million in Q1 2021 and bottomed at $2.9 million in Q4 2025.
- The 3-year median for Non-Current Deffered Revenue is $5.4 million (2024), against an average of $23.5 million.
- Peak annual rise in Non-Current Deffered Revenue reached 24.02% in 2025, while the deepest fall reached 43.78% in 2025.
- Tracing ACIU's Non-Current Deffered Revenue over 3 years: stood at $33.8 million in 2021, then tumbled by 84.58% to $5.2 million in 2024, then slumped by 43.78% to $2.9 million in 2025.
- Per Business Quant, the three latest ACIU Non-Current Deffered Revenue figures stand at $2.9 million (Q4 2025), $3.4 million (Q3 2025), and $4.3 million (Q2 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 225.10 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | - |
| 10 | AC Immune | 325.88 Mn | 211.53 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 2.93 Mn |
| Sep 30, 2025 | 3.38 Mn |
| Jun 30, 2025 | 4.34 Mn |
| Mar 31, 2025 | 4.40 Mn |
| Dec 31, 2024 | 5.21 Mn |
| Sep 30, 2024 | 5.53 Mn |
| Jun 30, 2024 | 5.72 Mn |
| Sep 30, 2021 | 33.76 Mn |
| Jun 30, 2021 | 66.90 Mn |
| Mar 31, 2021 | 102.86 Mn |
| Sep 30, 2019 | 1.11 Mn |
| Jun 30, 2019 | 1,897.88 |
| Mar 31, 2019 | 2.64 Mn |